Kolinpharma SpA
MIL:KIP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Kolinpharma SpA
Income from Continuing Operations
Kolinpharma SpA
Income from Continuing Operations Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Income from Continuing Operations | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Kolinpharma SpA
MIL:KIP
|
Income from Continuing Operations
€342.3k
|
CAGR 3-Years
-17%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Intercos SpA
MIL:ICOS
|
Income from Continuing Operations
€50.1m
|
CAGR 3-Years
4%
|
CAGR 5-Years
6%
|
CAGR 10-Years
N/A
|
|
|
Pharmanutra SpA
MIL:PHN
|
Income from Continuing Operations
€24m
|
CAGR 3-Years
1%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Enervit SpA
MIL:ENV
|
Income from Continuing Operations
€4.3m
|
CAGR 3-Years
1%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Kolinpharma SpA
Glance View
Kolinpharma SpA engages in the research, development, and marketing of food supplements based on natural raw materials of natural origin. The company is headquartered in Lainate, Milano and currently employs 110 full-time employees. The company went IPO on 2018-03-09. The firm offers a number of products, including almetax, which is a food supplement based on alpha-lipoic acid, L-tryptophan, turmeric, vitamins B5, b6 AND C, Chromium picolinade and Zinc that acts synergistically on the main symptoms of menopause; Almatex easy, which enables the preservation of the general well-being of the body; Dolasix, which is a food supplement that acts synergistically in favor of the normal functionality of cartilages and connective tissues; Ivuxur, which is a food supplement based on cranberry ( dried cranberry extract), D-mannose, bearberry and Zinc that is used in the treatment of unary tract infections; Milesax, which is a food supplement based on magnesium bisglycinate, boswellia serrata and L-tryptophan that acts synergistically on contractures, muscles relaxation and mood during the rehabilitation and recovery phases, and Xinepa, among others.
See Also
What is Kolinpharma SpA's Income from Continuing Operations?
Income from Continuing Operations
342.3k
EUR
Based on the financial report for Dec 31, 2022, Kolinpharma SpA's Income from Continuing Operations amounts to 342.3k EUR.
What is Kolinpharma SpA's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 3Y
-17%
Over the last year, the Income from Continuing Operations growth was -46%. The average annual Income from Continuing Operations growth rates for Kolinpharma SpA have been -17% over the past three years .
